abstract |
Disclosed is a pharmaceutical product for prevention and treatment of sporadic amyotrophic lateral sclerosis, which contains, as an active ingredient, a substance that is selected from the group consisting of (a) leucomycins and oleandomycins, (b) cyclophosphamides, and (c) a interferons, said substance having an effect of activating ADAR2 activity in motor neuron. |